Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102)

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Rituximab is an antibody made in a laboratory. It binds to lymphoma cells and kills them. Treatment of recurrent B-cell lymphoma with rituximab may delay or prevent relapses. A total of 166 patients with recurrent B-cell lymphoma were given intravenous rituximab once a week for 4 weeks. The patients' tumors were measured before and after treatment. Ten patients had a complete response and 70 patients had a partial response to rituximab. The median duration of response was 11.2 months.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Biogen
• Treatments: Rituximab

Criteria

Inclusion Criteria:

• Diagnosis of relapsed, low-grade or follicular B-cell lymphoma

• CD20-positive lymphoma

• Progressive, measurable disease

• Sign informed consent

• 3 weeks beyond standard therapy

• Good performance status

• Adequate hematologic, renal, and hepatic function

Exclusion Criteria:

• Chronic lymphocytic leukemia

• Lesions greater than or equal to 10 cm in diameter

• CNS lymphoma

• AIDS-related lymphoma

• Pleural effusions or ascites secondary to lymphoma

• Active, opportunistic infection

• Serious nonmalignant disease

• Prior investigational therapies, including prior anti-CD20 therapy

• Recent major surgery